Slide 1: BIOLASE presentation, May 29, 2013
Exhibit 99.1 Fredbiolase May The PAGE Furry, 29, 1 2013CFO Total –LeSolution Parker Meridien, Clinical R+D NewIndustry York Nasdaq: leading+ BIOL Certification Practice Integration Service+ Support
Slide 2: Safe Harbor Statement
Safebiolase This “anticipates,” include inform materially looking conditions, other The PAGE Harbor presentation factors 2you projections statements and aof Total Statement including domestic “expects,” such adversely Solution may include, about changes. contain economic those “intends,” from our Cl
Slide 3: Revolutionizing Surgery in Dentistry and Medicine
BIOLASE How? Conventional WaterLase antifungal The PAGE biolase Through 3 andisTotal Revolutionizing asurgical can disruptive theSolution drastically science devices technology Clinical of WaterLase! reduce Surgery include R+D the that the in Industry risk Dentistry is scalpel, changing of cross lea
Slide 4: Company Overview
BIOLASE We dental Gross Projecting The PAGEare also biolase revenue imaging 4focused market revenue Company Total of equipment, on and $58.5M Solution developing, ofdistribute: Overview $68M inClinical CAD/CAM to 2012, $72M manufacturing, $48.9M R+D forintraoral Industry 2013. in 2011; and scanners,
Slide 5: WaterLase is a revolutionary all-tissue laser
WaterLase There Significantly Extensive The PAGEbiolase is5 very patent All-Tissue isTotal reduces alittle atraumatic protection. Solution trauma cross Lasers and or Clinical contamination. Multiple bleeding, revolutionary R+D other NoIndustry heat medical method or leading+ vibration applications.
Slide 6: How It Works: High Speed Cutting
Howbiolase The PAGEIt6Works: Total WaterLase Solution High Clinical Speed R+D Cutting Industry leading+ Certification Practice Integration Service+ Support
Slide 7: WaterLase Side by Side with Drill
WaterLase The PAGEbiolase 7 SideTotalbySolution Side with Clinical Drill R+D Industry leading+ Certification Practice Integration Service+ Support
Slide 8: WaterLase Soft Tissue Lingual Frenectomy
WaterLase The PAGEbiolase 8 SoftTotal Tissue Solution Lingual Clinical Frenectomy R+D Industry leading+ Certification Practice Integration Service+ Support
Slide 9: Traditional Dentistry
Traditional The PAGEpainting biolase 9 Dentistry Total Cavadenti, Solution theClinical Tooth Puller, R+D Industry by Caravaggio, leading+circa Certification 1608 Practice Integration Service+ Support
Slide 10: WaterLase Atraumatic Pediatric Tooth Extraction
WaterLase The PAGEWaterLase biolase 10 Atraumatic Total aiming Solution Pediatric beamClinical doesTooth not R+Dcut Extraction Industry the tissue leading+ or generate Certification heat. ThePractice tissue isIntegration cut biologically, Service+ withSupport little or no pain, when the laser energi
Slide 11: Extensive Patent Portfolio
Extensive Issued U.S. Active International Total 352 Over The PAGE patents biolase 82 70% 183 11 &50Pending 169 Patent are 132 currently Total 101 352 related Portfolio 119 Solution Total issued to 220 WaterLase Clinical & pending. R+D technology Industry & leading+ medical lasers. Certification Pra
Slide 12: Diode EPIC regulatory clearance
Diode EPIC regulatory cleared Soft portable iLase no The PAGE foot biolase Tissue 10 Soft-Tissue 12 pedal, for diode total clearance 3Surgery, Total unique diode power laser. Solution Dental solution uses: Whitening, late cord,Q3 Lasers Clinical or(EU) external Pain &R+D early Therapy. controls. Ind
Slide 13: In-Licensed Products
In-Licensed TRIOS digital NewTom medical The PAGE biolase 13 impression intra-oral grade andTotal Products Cefla imaging scanner Solution taking. 3D technology. cone and handheld Clinical beam cart: imaging R+D less scanner, cost, Industry products: operator’s less radiation leading+ control exposur
Slide 14: BIOLASE's Step Treatment Protocol
BIOLASE’s Step Diagnose treatment device WaterLase Treatment: surgical Impression laser The PAGE biolase Technology 14 WaterLase device protocol and MD all soft taking Total Total establish tissue iLase Turbo tissue BIOLASE Solution MDX Technology for DaVinci surgical portable, crowns Diode 3D Clini
Slide 15: Warning: Cross Contamination
Warning: Cross Sterilization 1. 2009, garnet Ioana The PAGE Dental CDC biolase Rizoiu, Vol. contamination laser 15 Health Patients defines 75, Total with techniques MS No.Magazine radial Solution cross-contamination and Urged 1. is 3.Roy aemitting Contaminated used to huge Clinical H. 2. Ask for Den
Slide 16: Dental Risks of Cross Contamination Are Real
Dental Earlier have Officials The PAGEArkansas Risks cost biolase been 16 Patients this of cannot screened ofyear, the Total Cross Department screenings Test be approximately Solution more Contamination so Positive far,specific of already 57 Clinical for Health have 7,000 HIV, about exceeds are hepa
Slide 17: WaterLase Eliminates Burs and Complex Files
WaterLase Burs Complex WaterLaseTips: 15% endodontic Autoclaving decontaminate Smooth bacteria YSGG Disposable Also 1. Contaminated emitting Wanda The PAGE Dental biolase of and eliminates 17 laser Gordon, “sterilized” tip like tips Endo Burs and Technology surface files tips Total energy abrasive f
Slide 18: Current Market Opportunity
BIOLASE’s 176,000 rapid Current approx. Each 21Dental PAGE incremental growth BIOLASE 20,000+laser 5.0% market 1,200,000 The American dentists market Market World biolase 18 in ofFederation penetration. emerging systems Totaldental inSolution 1% Dental US opportunity Opportunity market sold& practic
Slide 19: Dominant Hard-tissue Dental Laser Market Position
Dominant Hard-tissue BIOLASE 45% 80% The PAGEbiolase 19 Market Market Dental Total Solution Position Share Laser Market Clinical Total R+DDental Industry Laser leading+ MarketCertification Practice Integration Service+ Support
Slide 20: Sales Returned to Targeted Direct Sales Model
Sales Returned 37 10 Targeted Current: Planned: The PAGE direct inside biolase and 20Irvine, plans Dubai outside sales to Marketing Total direct for representatives (UAE) CA(USA), sales. Solution sales 42 45and model outside Clinical Floss Rioand inde reps (Germany), North Janero lead R+D and genera
Slide 21: Gross Revenue Growth and Turnaround
Gross F. Turnaround 2010 Growth $80 1998 In The PAGE Pignatelli millions $70 biolase under 1999 Revenue 21through $602000 direction Total through departs $50direct 2001 $40 Solution and the of $30 2002 sales new reestablishment management $20 Clinical 2003 force management $102004 in$0 R+D North ent
Slide 22: Continued Significant Growth Strategy
Continued Significant Growth Additional Two Expand The PAGEWaterLase biolase 510(k) 22into Strategy of Imaging adoption new demad Total submissions newproduct product markets Solution for Division ofour core line, introductions currently beyond EPIC Clinical laser particularly (cone 10 products. den
Slide 23: New Products and Revenue Growth
Gross millions $15.0 $20.0 $0.0 $5.0 New WaterLase® Introduced CE Launched The PAGEMark biolase management Revenue 23$10.0 &Cefla’s 3Shape’s WaterLase® iLase™ DaVinci Total FDA iPlus™ In and Solution clearance NewTom with hand-held Influencers TRIOS™ Imaging™ all-tissue F.MDX™ Pignatelli Clinical fo
Slide 24: Summary of Q1 Revenue 2004-2013
Summary millions $20.0 $25.0 $10.0 Q1 The $14.6 $12.3 $10.6 $4.4 $6.6 $19.0 $15.1 $16.9 $16.8 $14.5 PAGE ‘04 biolase $5.0 24 Q1 $15.0 of$0.0 ‘05 Total Q1: In Q12004-2013 Solution ‘06 Q1 ‘07 Clinical Q1 ‘08R+D Q1Industry ‘09 Q1 ‘10 leading+ Q1 ‘11Certification Q1 ‘12 Q1 ‘13Practice Integration Servic
Slide 25: Investment Considerations
Investment Ongoing Addressing Entering Diode competition Significant The PAGEbiolase soft 25inflection growth tissue opportunities Considerations $50B Total for WaterLase. in lasers Solution dental point corehavebecome WaterLase laser for inClinical &We other diode Expectations market strongly medic
Slide 26: Opportunities Outside of Dentistry
Opportunities BIOLASE Ophthalmology: FDA Orthopedics: EPIC distributors The PAGE biolase clearance V-Series diode 26 currently and/or Total lasers: Outside for forSolution veterinary inside core holds ofWaterLase Dentistry sales 19 Clinical market; issued group. iPlus R+D and 70,000 as Industry 21ap
Slide 27: BIOLASE Facilities and Corporate Headquarters
57,000 Sales facility BIOLASE The PAGE biolase offices 27 sq. at corporate ft. Today Corporate Europe Total in facility Floss Solution inHQ in Floss, (Germany), Headquarters Irvine, with Clinical Germany access California, Madrid R+D intoIrvine, state-of-the-art Industry (Spain), includes California
Slide 28: Federico Pignatelli and Fred Furry, New York, May 2013
Federico May The PAGEbiolase 13-17, 28Pignatelli, Total 2013 Solution –New Chairman York Clinical City & CEOR+D Fred Industry Furry,leading+ COO & CFO Certification Practice Integration Service+ Support